The investigational drug demonstrated robust STAT6 degradation in blood and skin that was well tolerated and safe in healthy volunteers.

Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out ...

Investigating allergy prevention, this research highlights early intervention strategies and the promise of biologic ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

If you or someone you know has chronic asthma do read this article to know how biologics can potentially help in treating the condition ...

All participants will initially undergo a run-in period on standardised medium-dose ICS/LABA to confirm persistent lack of ...

The poster presentations will be available on Connect’s website under the Presentations and Publications section.

Children with uncontrolled, moderate to severe asthma used dupilumab or placebo for 52 weeks. The treatment group had significant decreases in annualized exacerbation rates compared with the ...

Dupilumab reduced airway inflammation and mucus burden and enhanced airway volume and flow, which led to better lung function and improved asthma control in patients with moderate to severe type 2 ...

And the takeaway from this for clinicians is I think we're pushing the envelope every time in asthma care. Certainly all of us know that dupilumab reduces nitric oxide levels, which is quite ...

Three abstracts evaluating dupilumab (Dupixent) for moderate-to-severe asthma were presented at the recent American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting: VESTIGE ...